About Dimension Therapeutics
Dimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company's gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company's lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: DMTX
- Previous Close: $1.90
- 50 Day Moving Average: $3.76
- 200 Day Moving Average: $5.69
- 52-Week Range: $25,043,000.00 - $1.65
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.79
- P/E Growth: 0.00
- Market Cap: $47.58M
- Outstanding Shares: 25,043,000
- Beta: 3.97
- Net Margins: -464.39%
- Return on Equity: -50.07%
- Return on Assets: -37.10%
Companies Related to Dimension Therapeutics:
- Debt-to-Equity Ratio: 0.07%
- Current Ratio: 5.43%
- Quick Ratio: 5.43%
What is Dimension Therapeutics' stock symbol?
Dimension Therapeutics trades on the NASDAQ under the ticker symbol "DMTX."
Where is Dimension Therapeutics' stock going? Where will Dimension Therapeutics' stock price be in 2017?
6 brokers have issued 1 year price targets for Dimension Therapeutics' stock. Their forecasts range from $3.00 to $20.00. On average, they anticipate Dimension Therapeutics' stock price to reach $10.83 in the next year.
When will Dimension Therapeutics announce their earnings?
Dimension Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 22nd 2017.
What are analysts saying about Dimension Therapeutics stock?
Here are some recent quotes from research analysts about Dimension Therapeutics stock:
- Cantor Fitzgerald analysts commented, "We are lowering our rating to Neutral from Overweight and price target to $3 from $32, following initial results from Dimension's Phase 1/2 Study with DTX101 in Hemophilia B. Results highlighted that DTX101 will require additional optimization to be competitive with currently ongoing Hemophilia B gene therapy programs. While DTX101 was able to achieve meaningful peak FIX levels, these levels declined significantly in all patients. In addition, five of six patients demonstrated elevated levels of ALTs, which could hinder the company's ability to dose higher. Seeing the need for additional optimization for the hemophilia B program, we are moving to the sidelines and adjusting our price target." (1/31/2017)
According to Zacks Investment Research, "Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company's pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts. " (1/13/2017)
Who owns Dimension Therapeutics stock?
Dimension Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (21.55%), FMR LLC (19.54%), New Leaf Venture Partners L.L.C. (8.22%), FIL Ltd (6.74%), Janus Capital Management LLC (4.42%) and State Street Corp (0.74%). Company insiders that own Dimension Therapeutics stock include K Reed Clark and Rishi Gupta.
Who sold Dimension Therapeutics stock? Who is selling Dimension Therapeutics stock?
Dimension Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC.
Who bought Dimension Therapeutics stock? Who is buying Dimension Therapeutics stock?
Dimension Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including New Leaf Venture Partners L.L.C., Renaissance Technologies LLC, State Street Corp and Turner Investments LLC.
How do I buy Dimension Therapeutics stock?
Shares of Dimension Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Dimension Therapeutics stock cost?
One share of Dimension Therapeutics stock can currently be purchased for approximately $1.90.